Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 5/2017

01-05-2017 | Original Article – Cancer Research

Hepatic inflammation-fibrosis-cancer axis in the rat hepatocellular carcinoma induced by diethylnitrosamine

Authors: Yong-fang Ding, Zhen-hui Wu, Ying-jie Wei, Luan Shu, Yun-ru Peng

Published in: Journal of Cancer Research and Clinical Oncology | Issue 5/2017

Login to get access

Abstract

Purpose

Hepatocellular carcinoma (HCC) cases are closely associated with chronic inflammation and fibrosis which is known as hepatic inflammation-fibrosis-cancer (IFC) axis. The aim of this study is to elucidate the development characteristics of the rat HCC model based on IFC axis.

Methods

The diethylnitrosamine (DEN)-induced rat HCC, which presents a stepwise histopathological progression that is similar to human HCC, was used to analyze the features of the different stages (inflammation, fibrosis, cancer). Rats were injected DEN at a dose of 30 mg/kg body weight twice a week for 11 weeks and the animals were observed until week 20. Time series sera and organ samples from the DEN animal model were collected to evaluate the dynamic changes.

Results

It was found that serum biochemical indicators (AST, ALT, ALP, TP, T-BIL, IL-6, TNF-α) from DEN-treated group were higher than that from control group. Fibrosis-related index in serum and live tissue were increased, respectively, from week 4 after DEN treatment. The expression of TGF-β1 and α-SMA in DEN-treated group was higher than that in control group. JAK2/STAT3 signaling was significantly up-regulated in DEN-treated group compared to that in control group. The histological examination confirmed that the hepatocarcinogenesis model was successfully established, and 100% of the animals in the DEN-exposed group developed liver tumors at 20 weeks. According to the pathological changes, the model characterized resulted in three stages: the inflammation stage (week 2–6), the fibrosis stage (week 8–12), and the HCC stage (week 14–20).

Conclusions

The results suggested that the HCC development was associated with IFC axis. The serial progression of hepatocarcinogenesis was according to the sequence of hepatic inflammation, fibrosis and then hepatic tumor.
Literature
go back to reference Borbath I, Stärkel P (2011) Chemoprevention of hepatocellular carcinoma. Proof of concept in animal models. Acta Gastroenterol Belg 74:34–44PubMed Borbath I, Stärkel P (2011) Chemoprevention of hepatocellular carcinoma. Proof of concept in animal models. Acta Gastroenterol Belg 74:34–44PubMed
go back to reference Calès P, Boursier J, Chaigneau J et al (2010) Diagnosis of different liver fibrosis characteristics by blood tests in non-alcoholic fatty liver disease. Liver Int 30:1346–1354CrossRefPubMed Calès P, Boursier J, Chaigneau J et al (2010) Diagnosis of different liver fibrosis characteristics by blood tests in non-alcoholic fatty liver disease. Liver Int 30:1346–1354CrossRefPubMed
go back to reference Costentin CE, Roudot-Thraval F, Zafrani ES et al (2011) Association of caffeine intake and histological features of chronic hepatitis C. J Hepatol 54:1123–1129CrossRefPubMed Costentin CE, Roudot-Thraval F, Zafrani ES et al (2011) Association of caffeine intake and histological features of chronic hepatitis C. J Hepatol 54:1123–1129CrossRefPubMed
go back to reference Cubero FJ (2016) Shutting off inflammation: a novel switch on hepatic stellate cells. Hepatology 63:1086–1089CrossRefPubMed Cubero FJ (2016) Shutting off inflammation: a novel switch on hepatic stellate cells. Hepatology 63:1086–1089CrossRefPubMed
go back to reference Di Virgilio F (2014) Purinergic receptors in cancer and inflammation: from Rudolph Virchow to Geoff Burnstock. Purinergic signallling, vol 10. Springer, Netherlands, pp 657–658 Di Virgilio F (2014) Purinergic receptors in cancer and inflammation: from Rudolph Virchow to Geoff Burnstock. Purinergic signallling, vol 10. Springer, Netherlands, pp 657–658
go back to reference Ding Y, Peng Y, Li J et al (2013) Gualou Xiebai Decoction prevents myocardial fibrosis by blocking TGF-beta/Smad signalling. J Pharm Pharmacol 65:1373–1381CrossRefPubMed Ding Y, Peng Y, Li J et al (2013) Gualou Xiebai Decoction prevents myocardial fibrosis by blocking TGF-beta/Smad signalling. J Pharm Pharmacol 65:1373–1381CrossRefPubMed
go back to reference Elsharkawy AM, Mann DA (2007) Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis. Hepatology 46:590–597.CrossRefPubMed Elsharkawy AM, Mann DA (2007) Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis. Hepatology 46:590–597.CrossRefPubMed
go back to reference Farazi PA, Depinho RA (2006) Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6:674–687CrossRefPubMed Farazi PA, Depinho RA (2006) Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6:674–687CrossRefPubMed
go back to reference Hernandez–Gea V, Toffanin S, Friedman SL et al (2013) Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology 144:512–527CrossRef Hernandez–Gea V, Toffanin S, Friedman SL et al (2013) Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology 144:512–527CrossRef
go back to reference Knodell RG, Ishak KG, Black WC et al (1981) Forumlation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1:431–435CrossRefPubMed Knodell RG, Ishak KG, Black WC et al (1981) Forumlation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1:431–435CrossRefPubMed
go back to reference Li J, Sun Z, Zhang J et al (2011) A dual-targeting anticancer approach: soil and seed principle. Radiology 260:799–807CrossRefPubMed Li J, Sun Z, Zhang J et al (2011) A dual-targeting anticancer approach: soil and seed principle. Radiology 260:799–807CrossRefPubMed
go back to reference Ma W, Sze KM, Chan LK et al (2016) RhoE/ROCK regulates chemoresistance through NF-ΚB/IL-6/STAT3 signaling in hepatocellular carcinoma. Oncotarget 27:41445–41459. doi:10.18632/oncotarget.9441 Ma W, Sze KM, Chan LK et al (2016) RhoE/ROCK regulates chemoresistance through NF-ΚB/IL-6/STAT3 signaling in hepatocellular carcinoma. Oncotarget 27:41445–41459. doi:10.​18632/​oncotarget.​9441
go back to reference Peng Y, Ding Y (2015) Pharmacokinetics and tissue distribution study of caudatin in normal and diethylnitrosamine-induced hepatocellular carcinoma model rats. Molecules 20:4225–4237CrossRefPubMed Peng Y, Ding Y (2015) Pharmacokinetics and tissue distribution study of caudatin in normal and diethylnitrosamine-induced hepatocellular carcinoma model rats. Molecules 20:4225–4237CrossRefPubMed
go back to reference Santos NP, Colaco A, da Costa R M G (2014) N-diethylnitrosamine mouse hepatotoxicity: time-related effects on histology and oxidative stress. Exp Toxicol Pathol 66:429–436CrossRef Santos NP, Colaco A, da Costa R M G (2014) N-diethylnitrosamine mouse hepatotoxicity: time-related effects on histology and oxidative stress. Exp Toxicol Pathol 66:429–436CrossRef
go back to reference Tachi Y, Hirai T, Miyata A et al (2015) Progressive fibrosis significantly correlates with hepatocellular carcinoma in patients with a sustained virological response. Hepatol Res 45:238–246. doi:10.1111/hepr.12331 CrossRefPubMed Tachi Y, Hirai T, Miyata A et al (2015) Progressive fibrosis significantly correlates with hepatocellular carcinoma in patients with a sustained virological response. Hepatol Res 45:238–246. doi:10.​1111/​hepr.​12331 CrossRefPubMed
go back to reference Tyler PD, Mcdevitt JL, Sheu AY et al (2013) Seven-tesla magnetic resonance imaging accurately quantifies intratumoral uptake of therapeutic nanoparticles in the McA rat model of hepatocellular carcinoma: preclinical study in a rodent model. Investig Radiol 49:87–92CrossRef Tyler PD, Mcdevitt JL, Sheu AY et al (2013) Seven-tesla magnetic resonance imaging accurately quantifies intratumoral uptake of therapeutic nanoparticles in the McA rat model of hepatocellular carcinoma: preclinical study in a rodent model. Investig Radiol 49:87–92CrossRef
go back to reference Uehara T, Pogribny I P, Rusyn I (2014) The DEN and CCl4-induced mouse model of fibrosis and inflammation-associated hepatocellular carcinoma. Curr Protoc Pharmacol 66:14.30.1–14.30.10 Uehara T, Pogribny I P, Rusyn I (2014) The DEN and CCl4-induced mouse model of fibrosis and inflammation-associated hepatocellular carcinoma. Curr Protoc Pharmacol 66:14.30.1–14.30.10
go back to reference Wong WS, Janssen H L A (2015) Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection? J Hepatol 63:722–732CrossRefPubMed Wong WS, Janssen H L A (2015) Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection? J Hepatol 63:722–732CrossRefPubMed
go back to reference Zhao H, Guo Y, Han R et al (2015) A novel anti-cancer agent Icaritin suppresses hepatocellular carcinoma initiation and malignant growth through the IL-6/Jak2/Stat3 pathway. Oncotarget 31:31927–31943. doi:10.18632/oncotarget.5578 Zhao H, Guo Y, Han R et al (2015) A novel anti-cancer agent Icaritin suppresses hepatocellular carcinoma initiation and malignant growth through the IL-6/Jak2/Stat3 pathway. Oncotarget 31:31927–31943. doi:10.​18632/​oncotarget.​5578
Metadata
Title
Hepatic inflammation-fibrosis-cancer axis in the rat hepatocellular carcinoma induced by diethylnitrosamine
Authors
Yong-fang Ding
Zhen-hui Wu
Ying-jie Wei
Luan Shu
Yun-ru Peng
Publication date
01-05-2017
Publisher
Springer Berlin Heidelberg
Published in
Journal of Cancer Research and Clinical Oncology / Issue 5/2017
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-017-2364-z

Other articles of this Issue 5/2017

Journal of Cancer Research and Clinical Oncology 5/2017 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.